Shigatoxin 1, mAb 13C4
Quantity:
100 µg
Catalog #:
HM6007
Related Products
The monoclonal antibody 13C4 recognizes the 1B subunit of Shiga-like toxin 1. Shiga-like toxins (SLTs), are also called Verotoxins. Enterohemorrhagic Escherichia coli (EHEC) strains which are primarily of serotypes 0157:H7, 026:H11 and O111:H8 have been incriminated as etiologic agents of hemorrhagic colitis and Hemolytic-uremic syndrome, a generalized disease characterized by acute renal failure, thrombocytopenia, and microangiopathic hemolytic anemia. There are several distinct E.coli SLTs. SLT-I and SLT-II are produced by EHEC. SLT-I and Shiga toxin share;99% deduced amino acid sequence homology, whereas SLT-I and SLT-II share about 60% deduced amino acid sequence homology. SLT-I and SLT-II are antigenically distinct. The protein structure of the toxin consists of two domains: the A polypeptide that inhibits protein synthesis by targeting ribosomes, and the B polypeptide pentamer that binds to the eukaryotic cell receptor globotriaosylceramide (Gb3) leading to receptor-mediated endocytosis.
| Product type | Monoclonal antibodies |
|---|---|
| Quantity | 100 µg |
| Formulation | 1 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin. |
| Application | Functional studies, Immuno assays, Western blot |
| Use | For Western blotting dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10. For inhibition of biological activity in vitro dilutions have to be made according to the amounts of toxin to be inactivated. |
| Isotype | Mouse IgG1 |
| Species | N/A |
| References | 1. Strockbine, N et al; Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect Immun 1985, 50: 695 2. Smith, M et al; Development of a hybrid Shiga holotoxoid vaccine to elict heterologous protection against Shiga toxins types 1 and 2. Vaccine 2006, 24: 4122 3. Smith, M et al; The 13C3 monoclonal antibody that neutralizes Shiga toxin type 1 (Stx1) recognizes three regions on the Stx1 subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide. Infect Immun 2006, 74: 6992 |
| Storage and stability | Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year. |
| Precautions | For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use of or derivation of this product. |
| Disease | Infectious diseases, Nephrology |
| Application: | Functional studies, Immuno assays, Western blot |
|---|---|
| Use: | For Western blotting dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10. For inhibition of biological activity in vitro dilutions have to be made according to the amounts of toxin to be inactivated. |
| References: | 1. Strockbine, N et al; Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect Immun 1985, 50: 695 2. Smith, M et al; Development of a hybrid Shiga holotoxoid vaccine to elict heterologous protection against Shiga toxins types 1 and 2. Vaccine 2006, 24: 4122 3. Smith, M et al; The 13C3 monoclonal antibody that neutralizes Shiga toxin type 1 (Stx1) recognizes three regions on the Stx1 subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide. Infect Immun 2006, 74: 6992 |
|---|
CoA-TDS HM4000-6000
Protocol
